Connect Sign In
ARUP’s Innovation Central Laboratory will serve as an ecosystem for validating technologies and accelerating next generation diagnostics from concept to commercialization.
ARUP is the first U.S. lab to validate Rarity Bioscience’s ultrasensitive superRCA™ assay, which advances high-precision mutation detection and supports innovation in clinical and trial settings.
In his new role, Adam Barker, PhD, will lead operational innovation to support ARUP’s growth while maintaining the highest quality.
RIDGEWATER, N.J.—Recordati Rare Diseases Inc. today announced the presentation of new data detailing advances in the understanding of Castleman disease (CD), a group of rare immune system disorders characterized by abnormal lymph node enlargement and systemic inflammatory symptoms that can be…
The RESULTS Act offers meaningful reform to a flawed system and will ultimately benefit patients, support innovation, and create stability within the clinical laboratory community.
An article describing ARUP’s validation of an artificial intelligence (AI) solution to detect gastrointestinal parasites in wet mounts has been published in the Journal of Clinical Microbiology.
ARUP is the largest lab to receive reaccreditation under the updated ISO 15189 standard, an achievement that highlights the company’s technical excellence, commitment to quality, and innovation.
ARUP Laboratories now offers a test for pTau 217 to aid in the detection of Alzheimer’s disease pathology. This test is minimally invasive and more accessible than other types of diagnostic testing.
The rule and its compliance deadlines are no longer in effect, benefiting patient care, innovation, and the greater laboratory community, ARUP leaders said.
Pramana, Inc., and ARUP are collaborating to improve the assessment of bone marrow biopsies and address other key diagnostic challenges in hematopathology.
